Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remissionSumithira Vasu, Clara D. Bloomfield, Jessica Kohlschmidt et al.|Blood Advances|2018Cited by 111
A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance)Ravi Vij, Steven M. Devine, Jennifer Le‐Rademacher et al.|Transplantation and Cellular Therapy|2019Cited by 29
Granulocyte Colony-Stimulating Factor–Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host DiseaseSumithira Vasu, Steven M. Devine, Natarajan Muthusamy et al.|Transplantation and Cellular Therapy|2015Cited by 22
Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and AboveIbrahim N. Muhsen, Kristen M. O'Dwyer, Anjali S. Advani et al.|Blood|2024Cited by 3
Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real worldAaron C. Logan, Razan Mohty, Fevzi Yalniz et al.|Blood|2025Cited by 2